Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
487 questions in 49 reviews · Breast Cancer
current versionsNo studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sentinel node biopsy vs full axillary surgery All‐cause mortality · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 1.05 [0.89, 1.25] | 3 studies · 6352 participants | Moderate |
Sentinel node biopsy vs full axillary surgery Lymphoedema Patient‐reported lymphoedema of any severity · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.33 [0.15, 0.86] | 3 studies · 815 participants | Low |
Sentinel node biopsy vs full axillary surgery Subjective arm movement impairment · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.38 [0.22, 0.67] | 2 studies · 877 participants | Very low |
Yoga vs no therapy Health‐related quality of life (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 10 studies · 675 participants | Moderate |
Yoga vs psychosocial/educational interventions Anxiety (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 3 studies · 195 participants | Low |
Yoga vs psychosocial/educational interventions Fatigue (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 2 studies · 106 participants | Moderate |
Yoga vs psychosocial/educational interventions Sleep disturbances (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 2 studies · 119 participants | Very low |
Yoga vs exercise Health‐related quality of life Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 3 studies · 233 participants | Very low |
Yoga vs exercise Fatigue Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 3 studies · 233 participants | Very low |
Yoga vs no therapy Health‐related quality of life (medium‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 2 studies · 146 participants | Low |
Yoga vs no therapy Depression (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 7 studies · 496 participants | Low |
Yoga vs no therapy Anxiety (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 6 studies · 346 participants | Very low |
Yoga vs no therapy Fatigue (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 11 studies · 883 participants | Moderate |
Yoga vs no therapy Fatigue (medium‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 2 studies · 146 participants | Low |
Yoga vs no therapy Sleep disturbances (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 6 studies · 657 participants | Moderate |
Yoga vs psychosocial/educational interventions Health‐related quality of life (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 2 studies · 153 participants | Very low |
Yoga vs psychosocial/educational interventions Depression (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women… (2017) · Cochrane | no estimate extracted | 4 studies · 226 participants | Moderate |
Fulvestrant vs other endocrine treatment Time to progression · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | HR 0.95 [0.89, 1.02] | 9 studies · 4258 participants | Moderate |
Fulvestrant vs other endocrine treatment Clinical benefit rate · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | RR 1.03 [0.97, 1.1] | 9 studies · 4105 participants | High |
Fulvestrant vs other endocrine treatment Mortality · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | HR 0.97 [0.87, 1.09] | 5 studies · 2480 participants | High |
Fulvestrant vs other endocrine treatment Vasomotor toxicity · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | RR 1.02 [0.89, 1.18] | 8 studies · 3544 participants | High |
Fulvestrant vs other endocrine treatment Arthralgia · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | RR 0.96 [0.86, 1.09] | 7 studies · 3244 participants | High |
Fulvestrant vs other endocrine treatment Gynaecological toxicity · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | RR 1.22 [0.94, 1.57] | 6 studies · 2848 participants | High |
Fulvestrant vs other endocrine treatment Quality of life · women with hormone‐sensitive advanced breast cancer Fulvestrant for hormone‐sensitive metastatic breast cancer (2017) · Cochrane | no estimate extracted | 4 studies · 4 participants | High |
Intervention NR Quality of Life FACT‐B Functional Assessment of Cancer Therapy ‐ Breast Cancer Specific Scale from: 0‐144 · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 7 studies · 764 participants | Moderate |
Intervention NR Quality of Life EORTC European Organisation for Research and Treatment of Cancer ‐ Global Scale from: 0‐100 · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 6 studies · 299 participants | Moderate |
Intervention NR Quality of Life QoL Breast Cancer Quality of Life ‐ Breast Cancer Overall · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 2 studies · 111 participants | Very low |
Intervention NR Quality of Life ‐ SF‐36 (Physical) SF‐36 Physical Function Scale from: 0‐100 · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 2 studies · 308 participants | Low |
Intervention NR Anxiety Hospital Anxiety and Depression Scale · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 5 studies · 253 participants | Low |
Intervention NR Depression Hospital Anxiety and Depression Scale · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 4 studies · 213 participants | Low |
Intervention NR Fatigue Brief Fatigue Inventory · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | 3 studies · 127 participants | Low |
Intervention NR *CI: Confidence interval · breast cancer survivors Home‐based multidimensional survivorship programmes for breast cancer survivors (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emotional distress · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Uncertainty · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anxiety at end of intervention · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | 1 study · 58 participants | Low |
Intervention NR Depression at end of intervention · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | 2 studies · 120 participants | Very low |
Intervention NR Quality of life post intervention · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | 2 studies · 140 participants | Very low |
Intervention NR Quality of life 12 months post intervention · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | 1 study · 78 participants | Low |
Boost vs no boost Local control: recurrence at 5 years · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | HR 0.64 [0.55, 0.75] | 5 studies · 8315 participants | Low |
Boost vs no boost Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | HR 1.04 [0.94, 1.14] | 2 studies · 6342 participants | Moderate |
Boost vs no boost Disease‐free survival: disease progression/mortality at 5 years · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | HR 0.94 [0.87, 1.02] | 3 studies · 6549 participants | Low |
Boost vs no boost Late toxicity, pBRA · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | MD 0.38 | 2 studies · 1526 participants | Very low |
Boost vs no boost Cosmesis, panel scored: fair or poor · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | OR 1.41 [1.07, 1.85] | 2 studies · 1116 participants | Low |
Boost vs no boost Cosmesis, physician‐scored: fair or poor · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | OR 1.58 [0.93, 2.69] | 2 studies · 592 participants | Very low |
Boost vs no boost Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | HR 0.62 [0.52, 0.73] | 3 studies · 6963 participants | High |
Boost vs no boost Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer Tumour bed boost radiotherapy for women after breast‐conserving surgery (2017) · Cochrane | HR 0.65 [0.53, 0.81] | 2 studies · 5058 participants | High |
Summary of findings: Non‐intensive vs intensive follow‐up Overall survival · women treated for early breast cancer Follow‐up strategies for women treated for early breast cancer (2016) · Cochrane | HR 0.98 [0.84, 1.15] | 2 studies · 2563 participants | High |
Summary of findings: Non‐intensive vs intensive follow‐up Disease‐free survival · women treated for early breast cancer Follow‐up strategies for women treated for early breast cancer (2016) · Cochrane | HR 0.84 [0.71, 1] | 2 studies · 2563 participants | Low |
Summary of findings: Non‐intensive vs intensive follow‐up Quality of life4 · women treated for early breast cancer Follow‐up strategies for women treated for early breast cancer (2016) · Cochrane | no estimate extracted | 1 study · 639 participants | High |
Summary of findings: Decentralised vs centralised follow‐up Overall survival · women treated for early breast cancer Follow‐up strategies for women treated for early breast cancer (2016) · Cochrane | HR 1.07 [0.64, 1.78] | 1 study · 968 participants | Moderate |